Jeff George has led Sandoz since October 2008. Sandoz is the world’s second-largest generic pharmaceutical company globally with 2011 sales of USD 9.5 billion. Sandoz employs over 24,000 people in more than 130 countries, and its product price points are accessible to nearly 90% of the world’s population. Sandoz is a global leader in differentiated generics such as injectables and is the pioneer and #1 global player in the emerging field of biosimilars, or “follow on biologics”.

Prior to assuming his current position, Mr George was Head of Emerging Markets for the Middle East, Africa, Southeast Asia and the CIS countries for Novartis Pharma, where he led a team of over 3,000 people across more than 65 markets. He joined Novartis in January 2007 as Head of Western & Eastern Europe for Novartis Vaccines, where he was responsible for 25 markets from the UK to Russia.

Before joining Novartis, Mr George was Senior Director of Strategic Planning and Business Development at Gap Inc. Prior to this, he was an Engagement Manager at McKinsey & Company and has also worked in emerging markets private equity in South Africa and the US.

Mr George holds an MBA from Harvard University and a Masters from Johns Hopkins University’s School of Advanced International Studies (SAIS). He also holds a BA in international relations from Carleton College.

Dr Jan Groen joined MDxHealth in 2010 and has more than 25 years of experience in the clinical diagnostic industry, with a particular focus on emerging technologies, product development and commercialization. Dr Groen was previously the President and Chief Operating Officer of Agendia where he was responsible for their United States and European diagnostic operations. Prior to this, he served as Vice-President of Research & Development at Focus Diagnostics, a subsidiary of Quest Diagnostics, in California. Dr Groen has held numerous management and scientific positions at ViroClinics, the Erasmus Medical Center, and Akzo-Nobel. He is a supervisory board member of IBL International. Dr Groen holds a PhD from the Erasmus University Rotterdam and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.

Arthur Higgins is employed as Senior Consultant with Blackstone Healthcare Partners of The Blackstone Group. He previously served as Chairman of the Board of Management of Bayer HealthCare, a developer and manufacturer of human and animal health products.

Prior to joining Bayer HealthCare in 2004, Mr Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, from 2001 to 2004. Prior to joining Enzon Pharmaceuticals, Mr Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is a past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is a member of the Board of Directors of Zimmer, Resverlogix Corp, Ecolab, and Catalent Pharma.

Mr Higgins graduated from Strathclyde University, Scotland and holds a B.S. in Biochemistry.

Andrew Jack is the Pharmaceuticals Correspondent at the Financial Times. Prior to this he has held a series of posts including Accounting and Tax Correspondent, Paris Correspondent, and Moscow Bureau Chief.

Mr Jack joined the Financial Times in 1990. He was one of a group of journalists to be awarded the 1993 British Press Awards Reporting Team of the Year accolade for coverage of the Robert Maxwell affair.

He started his career as a public policy consultant and subsequently spent a year at the mayor’s office in New York as an Economic Development Officer. 

He graduated from Cambridge University with an honours degree in geography and was the Joseph Hodges Choate Memorial Fellow at Harvard University in 1988-89.  

The latest edition of his book, Inside Putin’s Russia, was published in paperback in the US at the end of 2005. He is the author of The French Exception, and previously wrote the specialist reports Insurance in France, Networking and Life at the Top. 

Mr Jack regularly appears on TV and radio.

Jan Lundberg is Executive Vice President for Science and Technology and President of Lilly Research Laboratories. He is also a member of the company’s executive committee.

Dr Lundberg joined Eli Lilly and Company January 2010, with responsibility for Research and the Development Center of Excellence. Prior to assuming his position at Lilly, Dr Lundberg served as Global Head of Discovery Research at AstraZeneca for ten years and was a member of their senior executive team.  

After receiving his medical education and PhD, Dr Lundberg served as Professor at the Department of Pharmacology, Karolinska Institute, Stockholm, Sweden.  He has authored more than 500 publications of original articles in international peer-reviewed journals and is listed as one of the highly cited authors by the Institute for Scientific Information. His work has focused on cell signaling in integrated systems using multiple mediators (peptides, purines, and nitric oxide) with translational applications to nervous system, endocrine, inflammation and cardiovascular areas. This research has been highly recognized and has received several awards. He has also been appointed as Honorary Doctor at the Pharmaceutical Faculty, Uppsala University (2006).

Dr Lundberg serves on PhRMA’s Science and Regulatory Committee and is on the boards of the Biotechnology Industry Organization (BIO) and BioCrossroads.

Dr John Noseworthy is President and Chief Executive Officer of Mayo Clinic, a not-for-profit organization operating in six states that is dedicated to medical care, research and education. Every year, more than a million people from all 50 states and nearly 150 countries come to Mayo Clinic for care.

Prior to his current appointment, Dr Noseworthy served as Chair of Mayo Clinic’s Department of Neurology, Medical Director of the Department of Development, and Vice Chair of the Mayo Clinic Rochester Executive Board.

During his tenure as CEO, Dr Noseworthy and his leadership team have created a strategic plan designed to ensure that Mayo Clinic remains a trusted resource for patients amid a rapidly changing health care environment – extending Mayo’s mission to new populations, providing care through more efficient delivery models, and increasing the personalization and immediacy of health care for all people. Examples of new initiatives include a proton beam cancer therapy program with two treatment centers – one in Phoenix and one in Rochester, Minnesota. – and development of a Mayo Clinic-affiliate network of high-quality medical practices throughout the country.

Dr Noseworthy is a Professor in the Department of Neurology, and continues to consult with patients. He specializes in multiple sclerosis and has spent more than two decades designing and conducting controlled clinical trials with generous support from the Medical Research Council of Canada, the Multiple Sclerosis Society of Canada, the National Multiple Sclerosis Society (USA) and the National Institutes of Health. Dr Noseworthy also is the author of more than 150 research papers, chapters, editorials and several books, including the three-volume textbook Neurological Therapeutics: Principles and Practice, now in its second edition. He also served as Editor-in-chief for Neurology, the official journal of the American Academy of Neurology.

Born in Melrose, Massachusetts, Dr Noseworthy received the MD degree from Dalhousie University in Halifax, Nova Scotia, Canada. He completed his neurology training at Dalhousie University and the University of Western Ontario, and a research fellowship at Harvard Medical School. He joined Mayo Clinic in 1990. He has received the Alumnus of the Year award from Dalhousie University (2005) and an Honorary Director of Science degree from the University of Western Ontario (2012). He is a Health Governor of the World Economic Forum.

Amy Schulman is an innovative, results-focused leader and a champion for diversity and women’s professional advancement. Since 2008 she has led the Pfizer Legal Division, which handles some of the most complex, challenging legal matters within a highly regulated industry. Additionally, Ms Schulman leads Pfizer's Consumer Healthcare (PCH) - a global $4 billion business that operates in more than 90 countries. She also serves as Executive Sponsor of Pfizer’s Global Women’s Council.

In 2012 Ms Schulman was instrumental in the sale of Pfizer Nutrition to Nestle for $11.85 billion after assuming responsibility for the business in 2010. While President of the $2.1 billion, global business and leading provider of infant formulas and other nutritional products, Ms Schulman led the business to increased profitability and above-market performance.

Ms Schulman is a recipient of the 2012 Margaret Brent Women Lawyers of Achievement Award. She was named one of 10 “leading lights” in The Financial Times’ 2011 U.S. Innovative Lawyers report and was listed on Forbes’ 2009 list of “The World’s Most Powerful Women.” A graduate of Wesleyan University, Ms Schulman earned her J.D. from Yale Law School. She serves on the Board of Directors for Wesleyan University.